Table 1.

Characteristics of the intention-to-treat population

VariablesValganciclovir (n=60)Valacyclovir (n=59)
Recipient
 Age (yr), mean±SD48±1350±11
 Sex (men)47 (78)37 (63)
 Cause of renal disease
  Chronic GN30 (50)21 (36)
  Polycystic kidney disease14 (23)10 (17)
  Hypertensive nephrosclerosis6 (10)11 (19)
  Diabetic nephropathy2 (3)6 (10)
  Chronic interstitial nephritis2 (3)4 (7)
  Other6 (10)7 (12)
 Preemptive transplantation6 (10)5 (8)
 Previous transplantation9 (15)7 (12)
 HLA mismatches, mean ± SD3.5±1.23.6±1.5
 Pretransplant PRA≥20%11 (18)9 (15)
 CMV serostatus
  D+/R−7 (12)4 (7)
  D+/R+44 (73)49 (83)
  D−/R+9 (15)6 (10)
Donor
 Age (yr), mean±SD50±1649±16
 Donor type (deceased)57 (95)54 (92)
 Expanded criteria donora34 (57)32 (54)
 Donation after cardiac death3 (5)3 (6)
 Dual kidney transplantation5 (9)3 (6)
 Primary immunosuppression
  Cyclosporin + mycophenolate mofetil25 (42)35 (59)
  Tacrolimus + mycophenolate mofetil35 (58)24 (41)
  No induction therapy25 (42)34 (58)
  Basiliximabb26 (43)14 (24)
  Thymoglobulin9 (15)11 (19)
  • Data are n (%) unless otherwise indicated. PRA, panel reactive antibody; CMV, cytomegalovirus; D, donor; R, recipient.

  • a According to the United Network for Organ Sharing criteria.

  • b P=0.04.